Morgan Stanley analyst Vikram Purohit maintains Sage Therapeutics (NASDAQ:SAGE) with a Equal-Weight and lowers the price target from $53 to $50.
November 9, 7:14 AM
HC Wainwright & Co. analyst Douglas Tsao maintains Sage Therapeutics (NASDAQ:SAGE) with a Neutral and lowers the price target from $55 to $50.
Loop Capital Initiates Coverage On Sage Therapeutics with Hold Rating, Announces Price Target of $41
November 1, 7:23 AM
Loop Capital analyst Esther Hong initiates coverage on Sage Therapeutics (NASDAQ:SAGE) with a Hold rating and announces Price Target of $41.
October 17, 10:49 AM
Sage Therapeutics Inc (NASDAQ:SAGE) and Biogen Inc (NASDAQ:BIIB) presented additional data from the Phase 3 SKYLARK Study of zuranolone in adult women with…
Sage Therapeutics And Biogen Present New Analyses At Psych Congress Further Evaluating The Efficacy And Safety Of Zuranolone
September 19, 6:31 AM
Sage Therapeutics, Inc. (NASDAQ:SAGE) and Biogen Inc. (NASDAQ:BIIB) today announced new analyses from across the development program for zuranolone, an investigational, oral, once-daily, 14-day treatment in clinical
August 2, 6:45 AM
Sage Therapeutics (NASDAQ:SAGE) reported quarterly losses of $(2.13) per share which beat the analyst consensus estimate of $(2.15) by 0.93 percent. This is a 16.39 percent decrease over losses of $(1.83) per share from